SPRY vs. IMNM, SAGE, OPK, ALXO, TNGX, ELVN, ETNB, ARQT, ZNTL, and TYRA
Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Immunome (IMNM), Sage Therapeutics (SAGE), OPKO Health (OPK), ALX Oncology (ALXO), Tango Therapeutics (TNGX), Enliven Therapeutics (ELVN), 89bio (ETNB), Arcutis Biotherapeutics (ARQT), Zentalis Pharmaceuticals (ZNTL), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical preparations" industry.
ARS Pharmaceuticals (NASDAQ:SPRY) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.
Immunome received 13 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave ARS Pharmaceuticals an outperform vote while only 67.65% of users gave Immunome an outperform vote.
ARS Pharmaceuticals has higher earnings, but lower revenue than Immunome. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
ARS Pharmaceuticals has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500.
68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 35.6% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 20.0% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ARS Pharmaceuticals has a net margin of 0.00% compared to Immunome's net margin of -761.92%. ARS Pharmaceuticals' return on equity of -22.24% beat Immunome's return on equity.
ARS Pharmaceuticals currently has a consensus price target of $18.50, suggesting a potential upside of 95.35%. Immunome has a consensus price target of $30.50, suggesting a potential upside of 98.96%. Given Immunome's higher possible upside, analysts plainly believe Immunome is more favorable than ARS Pharmaceuticals.
In the previous week, ARS Pharmaceuticals had 1 more articles in the media than Immunome. MarketBeat recorded 2 mentions for ARS Pharmaceuticals and 1 mentions for Immunome. ARS Pharmaceuticals' average media sentiment score of 0.85 beat Immunome's score of 0.66 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.
Summary
ARS Pharmaceuticals beats Immunome on 11 of the 17 factors compared between the two stocks.
Get ARS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARS Pharmaceuticals Competitors List
Related Companies and Tools
